The Newsroom
Markets·October 24, 2026 at 5:30 AM EDT·1 source

Moderna Investors Should Brace for More Whiplash

MRNA -1.2%
MRNA · last 30 trading days-1.2% since the news
News

What happened

  • Moderna’s stock price suffered another sharp fall.
  • Despite the decline, the stock price still assumes the drugmaker will achieve wild successes.

Why it matters

The report signals continued valuation and volatility risk for healthcare investors assessing Moderna’s future prospects.

Read more on YouBank

The Newsroom, ranked for your desk

About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.

Timeline

  1. EarlierOct 21
    Moderna is about to release the trial results for its cancer vaccine. A lot is riding on this data.
  2. EarlierOct 23
    Tango combo clears Rasonque bar, Takeda's Innovent bet gets early returns, plus more from #ESMO26
  3. EarlierOct 23
    The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
  4. First reported by The Wall Street JournalYesterday
    Moderna Investors Should Brace for More Whiplash

Sources (1)

  1. The Wall Street JournalYesterday
    Moderna Investors Should Brace for More Whiplash

Related

Read more on YouBank

The Newsroom, ranked for your desk

About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.

  • Why it matters to youEvery story matched to your watchlist, your contacts and your pipeline.
  • Follow developing storiesAn alert, and a push, the moment a story you follow moves.
  • Your briefing, read aloudA few minutes each morning with a chapter per story.
  • Brief modeSwipe through the day, a 20-second card each.